Volume 1 Issue 1
Qidwai Asim*, Neelam M, Appoo A and Anwari S
The article, "Assessing Parental Knowledge about Thalassemia, in a Thalassemia Center of Karachi, Pakistan", was published in 'The Journal of Genetic Counseling'; in December 2015 issue [1]. The study explored the level of knowledge about the disease among the parents of the suffering children. This could be directly proportionate with the poor literacy rate among the study population.
Cite this Article: Asim Q, Neelam M, Appoo A, Anwari S. Thalassemia Major: A study on the perception of parents about disease. Int J Blood Dis Dis. 2017; 1(1): 013-015.
Published: 12 December 2017
Case Report: Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumour in a Single Individual - the Choice of Therapy is a Shoo-In
Simon Kavanagh* and Jeffrey H. Lipton
Chronic myeloid leukaemia and gastrointestinal stromal tumours are rare diseases that, despite different genomic lesions, are sensitive to tyrosine kinase inhibition with imatinib. We report a case of a patient with both diagnoses and discuss the rationale for treatment.
Cite this Article: Kavanagh S, Lipton JH. Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumour in a Single Individual - the Choice of Therapy is a Shoo-In. Int J Blood Dis Dis. 2017; 1(1): 010-010.
Published: 11 October 2017
Munawar Hussain*, Hans P Wendel and Frank K Gehring
Heparin Induced Thrombocytopenia (HIT) is an unwanted immunological reaction to the usage of heparin as an anticoagulant yielding thrombosis rather than the positive anticoagulant effects. The patients under heparin usage for several days are prone to HIT and HIT is connected to the risk of life threatening thrombosis by virtue of intravasal platelet aggregation. The destructive effects of HIT constitute thrombocytopenia and the thromboembolic complications risks in veins and arteries. Normally, HIT symptoms are observed within 4 to 15 days after initiation of heparin therapy and platelet count declines to less than half of the initial value [1].
Cite this Article: Hussain M, Wendel HP, Gehring FK. Heparin induced Thrombocytopenia and its Tomorrow. Int J Blood Dis Dis. 2017; 1(1): 007-009.
Published: 06 September 2017
Shilpita Karmakar, Debasis Banerjee and Abhijit Chakrabarti*
Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder resulting from the malignant transformation of a hematopoietic stem cell and is characterised by Philadelphia chromosome that generates a BCR-ABL protein with constitutive tyrosine kinase activity. Patients with CML have been reported with high platelet count, platelet dysfunction and thrombohaemorrhagic complications. The mechanism underlying such complications of platelets in CML is not well understood. In order to understand the factors responsible we have used 2DE coupled with MALDI TOF/TOF mass spectrometry based identification and characterization of altered proteins in CML platelet samples to investigate the factors responsible for thrombohemorrhagic complications and the results have been validated by immunoblotting experiments. Our study has revealed elevated levels of enzymes like GST, LDH, calcium binding protein, calreticulin, regulatory protein 14-3-3 ζ, INTEGRIN and HSP60 that points towards presence of activated platelets and increased metabolic activity of platelets in CML patients. The altered levels of chaperones, regulatory and enzyme proteins indicate towards regulation of INTEGRIN binding and platelet activation. This is the first comparative proteomics study of platelets in CML. The results could provide an insight into better understanding of the pathophysiology of the disease.
Cite this Article: Karmakar S, Banerjee D, Chakrabarti A. Platelet Proteomics in Chronic Myeloid Leukemia. Int J Blood Dis Dis. 2017; 1(1): 001-006.
Published: 14 June 2017
Authors submit all Proposals and manuscripts via Electronic Form!
